GlassScriptPhysician profile
Paul J Grimm
NPI 1609841444
$3,588.78
in general payments reported to CMS, 2019-2025
27 companies · $14.89 in 2025
The $14.89 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $904 · 2021: $1,713 · 2024: $392 · 2025: $14.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $1,604.00 | 2019-2021 | |
| Amgen INC. | $532.96 | 2019-2020 | |
| Abbvie INC. | $491.59 | 2019-2025 | |
| Novo Nordisk INC | $159.67 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $107.74 | 2019-2020 | |
| Lilly USA, LLC | $83.31 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Janssen Biotech, INC. | $75.77 | 2020-2021 | |
| Amarin Pharma, INC. | $54.16 | 2020 | |
| Mallinckrodt Enterprises LLC | $45.79 | 2019 | |
| Genzyme Corporation | $45.55 | 2020 | |
| Ucb, INC. | $45.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.15 | 2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $40.82 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $39.19 | 2020-2021 | |
| Radius Health, INC. | $30.83 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $22.54 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $22.36 | 2019 | |
| Mylan Specialty L.P. | $20.20 | 2024 | Yupelri |
| Viiv Healthcare Company | $17.79 | 2024 | Rukobia |
| Merck Sharp & Dohme LLC | $16.95 | 2024 | Delstrigo, Isentress, Pifeltro |
| Regeneron Healthcare Solutions, INC. | $15.26 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.82 | 2024 | Quviviq |
| Hikma Pharmaceuticals USA | $12.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.41 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.